Alzheimer's disease (AD) is the result of abnormal processing of the amyloid precursor protein (APP) by β-secretase and γ-secretase, which leads to the formation of toxic β-amyloid peptides. The toxic β-amyloid peptides induce neuron death, memory problems, and AD development. Several APP mutations increase the risk of developing early-onset AD. However, the A673T mutation identified in the Icelandic population prevents AD development by reducing the cleavage of APP by β-secretase. In this study, we inserted the A673T mutation in human cells using the CRISPR prime editing (PE) technique. Repeated PE treatments resulted in the insertion of the A673T mutation in up to 49.2% of APP genes when a second nick was induced in the other DNA strand. When the protospacer adjacent motif used for PE was also mutated, up to 68.9% of the APP genes contained the protective A673T mutation. PE is a promising approach to introduce the A673T mutation precisely without mutating nearby nucleotides.
YangP, SunF. Aducanumab: the first targeted Alzheimer's therapy. Drug Discov Ther, 2021; 15:166–168. DOI: 10.5582/ddt.2021.01061.
3.
SosaLJ, CáceresA, DuprazS, et al.The physiological role of the amyloid precursor protein as an adhesion molecule in the developing nervous system. J Neurochem, 2017; 143:11–29. DOI: 10.1111/jnc.14122.
4.
ShengM, SabatiniBL, SüdhofTC. Synapses and Alzheimer's disease. Cold Spring Harb Perspect Biol, 2012; 4:a005777. DOI: 10.1101/cshperspect.a005777.
5.
HardyJ, SelkoeDJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002; 297:353–356. DOI: 10.1126/science.1072994.
6.
GanKJ, SilvermanMA. Dendritic and axonal mechanisms of Ca2+ elevation impair BDNF transport in Aβ oligomer-treated hippocampal neurons. Mol Biol Cell, 2015; 26:1058–1071. DOI: 10.1091/mbc.E14-12-1612.
7.
BilousovaT, MillerCA, PoonWW, et al.Synaptic amyloid-β oligomers precede p-tau and differentiate high pathology control cases. Am J Pathol, 2016; 186:185–198. DOI: 10.1016/j.ajpath.2015.09.018.
8.
KlementievaO, WillénK, MartinssonI, et al.Pre-plaque conformational changes in Alzheimer's disease-linked Aβ and APP. Nat Commun, 2017; 8:14726. DOI: 10.1038/ncomms14726.
9.
FornerS, Baglietto-VargasD, MartiniAC, et al.Synaptic impairment in Alzheimer's disease: a dysregulated symphony. Trends Neurosci, 2017; 40:347–357. DOI: 10.1016/j.tins.2017.04.002.
10.
BertramL, TanziRE. The genetics of Alzheimer's disease. Prog Mol Biol Transl Sci, 2012; 107:79–100. DOI: 10.1016/B978-0-12-385883-2.00008-4.
11.
HatamiA, MonjazebS, MiltonS, et al.Familial Alzheimer's disease mutations within the amyloid precursor protein alter the aggregation and conformation of the amyloid-β peptide. J Biol Chem, 2017; 292:3172–3185. DOI: 10.1074/jbc.M116.755264.
12.
Di FedeG, CataniaM, MorbinM, et al.A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science, 2009; 323:1473–1477. DOI: 10.1126/science.1168979.
13.
LanoiseléeHM, NicolasG, WallonD, et al.APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases. PLoS Med, 2017; 14:e1002270. DOI: 10.1371/journal.pmed.1002270.
14.
JonssonT, AtwalJK, SteinbergS, et al.A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature, 2012; 488:96–99. DOI: 10.1038/nature11283.
15.
KeroM, PaetauA, PolvikoskiT, et al.Amyloid precursor protein (APP) A673T mutation in the elderly Finnish population. Neurobiol Aging, 2013; 34:1518.e1–3. DOI: 10.1016/j.neurobiolaging.2012.09.017.
16.
Mengel-FromJ, JeuneB, PenttiT, et al.The APP A673T frequency differs between Nordic countries. Neurobiol Aging, 2015; 36:2909.e1–4. DOI: 10.1016/j.neurobiolaging.2015.07.011.
17.
XiaQ, YangX, ShiJ, et al.The protective A673T mutation of amyloid precursor protein (APP) in Alzheimer's disease. Mol Neurobiol, 2021; 58:4038–4050. DOI: 10.1007/s12035-021-02385-y.
18.
BenilovaI, GallardoR, UngureanuAA, et al.The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid-β (Aβ) aggregation. J Biol Chem, 2014; 289:30977–30989. DOI: 10.1074/jbc.M114.599027.
19.
MartiskainenH, HerukkaSK, StančákováA, et al.Decreased plasma β-amyloid in the Alzheimer's disease APP A673T variant carriers. Ann Neurol, 2017; 82:128–132. DOI: 10.1002/ana.24969.
20.
KimuraA, HataS, SuzukiT. Alternative selection of β-site APP-cleaving enzyme 1 (BACE1) cleavage sites in amyloid β-protein precursor (APP) harboring protective and pathogenic mutations within the Aβ sequence. J Biol Chem, 2016; 291:24041–24053. DOI: 10.1074/jbc.M116.744722.
21.
GuyonA, RousseauJ, BertinT, et al.Protective A673T mutation decreases amyloid-beta peptide production for a majority of APP genes containing a mutation responsible for a Familial Alzheimer Disease. bioRxiv, 2020. DOI:10.1101/2020.07.22.215616.
22.
GuyonA, RousseauJ, LamotheG, et al.The protective mutation A673T in amyloid precursor protein gene decreases Aβ peptides production for 14 forms of familial Alzheimer's disease in SH-SY5Y cells. PLoS One, 2020; 15:e0237122. DOI: 10.1371/journal.pone.0237122.
23.
KomorA, KimY, PackerM, et al.Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature, 2016; 533:420–424. DOI: 10.1038/nature17946.
24.
GuyonA, RousseauJ, BéginFG, et al.Base editing strategy for insertion of the A673T mutation in the APP gene to prevent the development of AD in vitro. Mol Ther Nucleic Acids, 2021; 24:253–263. DOI: 10.1016/j.omtn.2021.02.032.
25.
AnzaloneAV, RandolphPB, DavisJR, et al.Search-and-replace genome editing without double-strand breaks or donor DNA. Nature, 2019; 576:149–157. DOI: 10.1038/s41586-019-1711-4.
26.
ScholefieldJ, HarrisonPT. Prime editing—an update on the field. Gene Ther, 2021; 28:396–401. DOI: 10.1038/s41434-021-00263-9.
27.
KluesnerMG, NedveckDA, LahrWS, et al.EditR: a method to quantify base editing from Sanger sequencing. CRISPR J, 2018; 1:239–250. DOI: 10.1089/crispr.2018.0014.
28.
ClementK, ReesH, CanverMC, et al.CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat Biotechnol, 2019; 37:224–226. DOI: 10.1038/s41587-019-0032-3.
29.
KantorA, McClementsME, MacLarenRE. CRISPR-Cas9 DNA base-editing and prime-editing. Int J Mol Sci, 2020; 21:6240. DOI: 10.3390/ijms21176240.
30.
ZuoE, SunY, WeiW, et al.Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos. Science, 2019; 364:289–292. DOI: 10.1126/science.aav9973.
31.
DuanL, XuL, XuX, et al.Exosome-mediated delivery of gene vectors for gene therapy. Nanoscale, 2021; 13:1387–1397. DOI: 10.1039/D0NR07622H.
32.
PardridgeWM. Blood–brain barrier and delivery of protein and gene therapeutics to brain. Front Aging Neurosci, 2020; 11:373. DOI: 10.3389/fnagi.2019.00373.
33.
KimDY, MoonSB, KoJH, et al.Unbiased investigation of specificities of prime editing systems in human cells. Nucleic Acids Res, 2020; 48:10576–10589. DOI: 10.1093/nar/gkaa764.
34.
TornabeneP, TrapaniI, MinopoliR, et al.Intein-mediated protein trans-splicing expands adeno-associated virus transfer capacity in the retina. Sci Transl Med, 2019; 11:eaav4523. DOI: 10.1126/scitranslmed.aav4523.
35.
ChanKY, JangMJ, YooBB, et al.Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat Neurosci, 2017; 20:1172–1179. DOI: 10.1038/nn.4593.
36.
BeharryA, GongY, KimJC, et al.The AAV9 variant capsid AAV-F mediates widespread transgene expression in nonhuman primate spinal cord after intrathecal administration. Hum Gene Ther, 2021 Aug 26 [Epub ahead of print]; DOI: 10.1089/hum.2021.069.
37.
JinT, GuJ, LiZ, et al.Recent advances on extracellular vesicles in central nervous system diseases. Clin Interv Aging, 2021; 16:257–274. DOI: 10.2147/CIA.S288415.
38.
LamichhaneTN, RaikerRS, JaySM. Exogenous DNA loading into extracellular vesicles via electroporation is size-dependent and enables limited gene delivery. Mol Pharm, 2015; 12:3650–3657. DOI: 10.1021/acs.molpharmaceut.5b00364.
39.
BusattoS, IannottaD, WalkerSA, et al.A simple and quick method for loading proteins in extracellular vesicles. Pharmaceuticals (Basel), 2021; 14:356. DOI: 10.3390/ph14040356.
40.
MendellJR, Al-ZaidySA, Rodino-KlapacLR, et al.Current clinical applications of in vivo gene therapy with AAVs. Mol Ther, 2021; 29:464–488. DOI: 10.1016/j.ymthe.2020.12.007.
41.
RafiiMS, BaumannTL, BakayRA, et al.A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement, 2014; 10:571–581. DOI: 10.1016/j.jalz.2013.09.004.
42.
Drouin-OuelletJ, PircsK, BarkerRA, et al.Direct neuronal reprogramming for disease modeling studies using patient-derived neurons: what have we learned?. Front Neurosci, 2017; 11:530. DOI: 10.3389/fnins.2017.00530.
43.
SaitoT, MatsubaY, MihiraN, et al.Single APP knock-in mouse models of Alzheimer's disease. Nat Neurosci, 2014; 17:661–663. DOI: 10.1038/nn.3697.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
